VIKING HOLDINGS LTD(PEMBROKE) : JP MORGAN RAISES TARGET PRICE TO $138 FROM $112
JP Morgan has increased its target price for Viking Holdings Ltd (Pembroke) from $112 to $138. This adjustment was reported by Reuters on August 10, 2026.
News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
JP Morgan has increased its target price for Viking Holdings Ltd (Pembroke) from $112 to $138. This adjustment was reported by Reuters on August 10, 2026.
Viking Therapeutics (VKTX) recently reported wider Q2 losses and increased its funding flexibility through new equity offerings. Despite a recent 21% share price drop, the company has strong long-term returns. Analysts question if its current valuation, which pegs fair value at $92.72 (64.1% undervalued), …
Viking announced the delivery of its newest Nile River ship, the Viking Ptah, which accommodates 82 guests in 41 staterooms. The ship is purpose-built for the "Pharaohs & Pyramids" itinerary and features Viking's signature Scandinavian design. This addition is part of Viking's significant expansion …
Viking Holdings Ltd (NYSE: VIK) has scheduled a conference call for 8:00 a.m. Eastern Time on Wednesday, August 19, 2026, to discuss its second quarter 2026 financial results. The results will be released before the stock market opens on the same day. A webcast …
FMR LLC has filed a Schedule 13G disclosing a 5.3% stake in Viking Holdings Ltd (VIK), owning 16,993,566.73 common shares as of June 30, 2026. FMR LLC holds sole dispositive power over these shares and sole voting power over 16,177,750.27 shares. Abigail P. Johnson …
Shares in Viking Therapeutics (NASDAQ: VKTX) declined by 18.6% in July, according to data from S&P Global Market Intelligence. The decline came during a slow month for newsflow in its pipeline, as investors began to fret about the company's financial position. Viking Therapeutics' quiet …
Viking (NYSE: VIK) has opened bookings for its 2028-2029 ocean voyages, marking its largest ocean deployment to date with over 700 new departure dates. This expansion includes the introduction of two new ocean ships, the Viking Vega and Viking Leda, scheduled for delivery in …
Viking Therapeutics (NASDAQ:VKTX) has received a "Moderate Buy" consensus recommendation from brokerages, with an average 12-month price target of $97.88, significantly higher than its current share price. Despite recent insider stock sales by the CFO and CEO to cover tax obligations, institutional investors maintain …
Viking Holdings Ltd. (NYSE:VIK) has received an average "Moderate Buy" rating from nineteen research firms, with an average 12-month price target of $105.11. The company's shares are trading near record highs, having risen above key moving averages, and it recently outperformed revenue expectations with …
Swedish mining company Gruvaktiebolaget Viscaria has appointed Sandvik to provide an underground automated fleet and services for the restart of its copper mine in Kiruna, Sweden. The agreement entails Sandvik providing four DL432i longhole drills along with four Toro LH621i loaders, which will operate …
Arrowstreet Capital Limited Partnership significantly reduced its stake in Viking Holdings Ltd. by selling 92,752 shares, retaining 18,978 shares valued at $1.4 million. Despite this sale, institutional ownership remains high at 98.84%, with other major investors increasing their positions. Viking Holdings reported strong quarterly …
Viking Holdings finished 1.4% below its 52-week high after a 3.6% weekly gain, with the Trend Signal still active but volume running at just 0.7x its 13-week average.
Viking Holdings (VIK) has expanded its fleet with the delivery of Viking Dagur and announced further fleet expansions, leading to a strong stock performance. Despite a widely followed narrative suggesting the stock is 5.3% overvalued at $107.52 compared to a fair value of $102.09, …
Viking Therapeutics recently reported a wider Q2 net loss and expanded its funding options through a universal shelf registration and a $500 million at-the-market stock offering. While these moves provide capital to advance its obesity drug candidate VK2735 through trials, they also highlight the …
Viking Holdings has recently taken delivery of the Viking Dagur, a new 190-guest Longship, furthering its ambitious expansion plans that could see its river fleet grow to 114 ships by 2028. While this aligns with Viking's capacity-led investment model, it also intensifies concerns about …
Eastern Bank has purchased a new stake of $10.53 million in Viking Holdings Ltd. (NYSE:VIK) during the second quarter, acquiring 100,631 shares. Institutional investors now collectively own 98.84% of the company, and Viking maintains a "Moderate Buy" consensus rating with an average target price …
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Why Viking Therapeutics' VK2735 News Matters For Investors Viking Therapeutics (VKTX) has drawn fresh …
In late July 2026, Viking Therapeutics reported Q2 and first-half net losses of US$128.02 million and US$286.35 million respectively, while also filing a US$500 million at-the-market equity offering and an omnibus shelf registration covering multiple securities types. Despite these wider losses and fresh financing …
Viking Therapeutics (VKTX) could unlock substantial additional opportunities for VK2735 through less PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign …
Amundi increased its stake in Viking Holdings Ltd. (NYSE:VIK) by 31.7% in the first quarter, acquiring an additional 164,001 shares. Institutional investors collectively own 98.84% of the company, which holds an average "Moderate Buy" rating and a consensus price target of $104.06. While the …
Viking Cruises has taken delivery of its newest river ship, Viking Dagur, as part of its ongoing fleet expansion, reinforcing its focus on capacity growth in the river cruise segment. This delivery aligns with Viking Holdings' strategy to add more ships, capitalizing on investor …
Evolutionary Tree Capital Management LLC reduced its stake in Viking Holdings Ltd. (NYSE:VIK) by 26.3% in the first quarter of 2026, selling 9,645 shares and retaining 27,018 shares valued at approximately $1.99 million. Despite this sale, analysts maintain a "Moderate Buy" consensus rating for …
Viking Therapeutics is considered a highly speculative investment due to its clinical-stage status, limited operating history, and expected substantial operating losses. The company's reliance on licensed technologies from Ligand Pharmaceuticals and the uncertain prospects of its drug candidates further elevate its risk profile for …
Goldman Sachs has increased its price target for Viking Holdings to $120.00 per share, up from $108.00. This news was reported alongside Unity Software's fourth-quarter results, which showed a revenue increase of 35% year-over-year to $609 million, exceeding analyst estimates.
Search by ticker symbol or company name and select a result to open its chart.